September 25, 2023
The University of Cincinnati's Rhonna Shatz, DO, spoke with Healio about cognitive function during cancer survivorship.
October 17, 2023
The University of Cincinnati Cancer Center has joined the National Cancer Institute’s Experimental Therapeutics Clinical Trials Network (ETCTN), providing patients with access to cutting edge treatments only available through the network.
November 16, 2023
The University of Cincinnati Gardner Neuroscience Institute's Brandon Foreman recently published survey results identifying areas of consensus and needs for further research to develop a standard practice for comprehensively monitoring brain health in the intensive care unit.
August 15, 2022
Drs Melanie Cushion, Michael Farrell and Bruce Giffin have been named 2022 recipients of Daniel Drake Medals.
December 22, 2022
The University of Cincinnati's Christopher Richards, MD, co-authored an accompanying editorial to new research that showed high variability in the way EMS agencies document stroke cases, which was recently featured by MedPage Today.
February 19, 2024
Local 12 and the Cincinnati Business Courier highlighted the University of Cincinnati Cancer Center's Blood Cancer Healing Center, a comprehensive all-in-one facility dedicated solely to advancing research, treatment and wellness for blood cancer patients, opening this summer.
January 11, 2024
WVXU highlighted a new trial at the University of Cincinnati that will test an at-home tongue endurance exercise to improve patients’ swallowing function after a stroke.
April 1, 2024
The University of Cincinnati's Brandon Foreman joined the iHeart Cinci Podcast to discuss traumatic brain injuries, including signs to look for and how to discuss the topic with your doctor.
April 12, 2024
University of Cincinnati researchers will present abstracts at the American Academy of Neurology annual meeting 2024, April 13-18 in Denver, Colorado.
March 22, 2024
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.